News Archives - Page 1517 of 1555

ThursdayJun 08, 2017 11:45 am

NetworkNewsBreaks – AVEO Oncology’s (NASDAQ: AVEO) Phase 1/2 TiNivo Trial Advances to Phase 2

AVEO Oncology (NASDAQ: AVEO) this morning said it has progressed to the phase 2 portion of its phase 1/2 AVEO-sponsored TiNivo trial evaluating tivozanib in combination with Bristol-Myers Squibb’s Opdivo® in subjects with advanced renal cell carcinoma (RCC). The advancement follows the successful completion of the phase 1 dose escalation portion of the trial, results of which will be submitted for presentation at an upcoming scientific meeting. “As our registration strategy for single agent tivozanib reaches key inflection points, with a European regulatory decision expected in the near-term and readout of our US registration-directed TIVO-3 study expected in the first…

ThursdayJun 08, 2017 11:05 am

NetworkNewsBreaks – Amedica Corporation (NASDAQ: AMDA) Releases Preliminary Earnings Report for FY2016

Amedica Corporation (NASDAQ: AMDA), a company that develops and commercializes silicon nitride for biomedical applications, this morning announced its preliminary earnings report for the fourth quarter and fiscal year ended December 31, 2016, and provided a business updated related to its strategy and recent developments. Among the highlights, Amedica reported preliminary revenue of $3.6 million for the fourth quarter of 2016 and $15.2 million for the full year. Preliminary GAAP net loss for the 12-month period was $1.19 per share, down from a net loss of $5.50 per share in 2015. Looking ahead, Amedica notes that it expects to complete…

ThursdayJun 08, 2017 10:21 am

NetworkNewsBreaks – FuelCell Energy, Inc. (NASDAQ: FCEL) Reports Second Quarter 2017 Results; Shares Lower

FuelCell Energy, Inc. (NASDAQ: FCEL), a global leader in delivering clean, innovative and affordable fuel cell solutions for the supply, recovery and storage of energy, this morning reported its financial results for the fiscal quarter ended April 30, 2017. The company’s total revenues for the three-month period were $20.4 million, down from $28.6 million for the comparable prior year period. Likewise, FCEL’s net loss attributable to common shareholders for the quarter totaled $14.0 million, or $0.33 per basic and diluted share, down from $16.2 million, or $0.56 per basic and diluted share, for the second quarter of 2016. Per a…

WednesdayJun 07, 2017 12:25 pm

NetworkNewsBreaks – Novavax, Inc. (NASDAQ: NVAX) Announces Publication of Clinical Trial Data in Vaccine

Clinical-stage biotechnology company Novavax, Inc. (NASDAQ: NVAX) today announced that data from the second of two phase II trials of its RSV F protein recombinant nanoparticle vaccine candidate in women of childbearing age have been published in the journal Vaccine. This specific information was previously shared at scientific conferences, and top line results from this trial were originally announced in April 2014. “The Western Blot finding from this trial, which demonstrates a reduction in recent RSV infections of approximately 52% in the vaccine relative to the placebo arms, is consistent with the Western Blot data we reported from a comparable…

WednesdayJun 07, 2017 11:55 am

NetworkNewsBreaks – DragonWave, Inc. (NASDAQ: DRWI) Shares Surge on News of Contract with SmartSky Networks

DragonWave, Inc. (NASDAQ: DRWI), a global supplier of packet microwave radio systems, announced late Tuesday that it has been awarded a product supply and installation services contract from SmartSky Networks, a North American 4G LTE inflight service provider. Under the terms of this deal, SmartSky will deploy DragonWave’s Harmony Enhanced and Harmony Enhanced MC products to provide high-capacity backhaul for its ground to air 4G LTE network. “DragonWave is excited to be working with SmartSky on its innovative high capacity and low latency inflight offering. This application is ideally suited for Harmony Enhanced MC,” Peter Allen, president and CEO of…

TuesdayJun 06, 2017 9:27 am

NetworkNewsBreaks – SinglePoint, Inc. (SING) Teams with First Bitcoin Capital (BITCF) to Develop Bitcoin Payments Solution

Specialized holding company SinglePoint, Inc. (OTC: SING) this morning announced an initiative to develop a bitcoin payments solution in partnership with First Bitcoin Capital Corp. (OTC: BITCF), an industry-leading bitcoin and blockchain technology provider. Per the news release, the two companies have signed a joint venture agreement to develop and distribute a viable payments solution targeted at “high-risk payment verticals including the cannabis industry” in order to “fill the payments gap that currently exists.” Through this new partnership, SinglePoint and First Bitcoin Capital intend to focus on their respective core strengths in order to build and supply the best bitcoin…

TuesdayJun 06, 2017 8:58 am

NetworkNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Announces Engagement of Venture Building Firm Launch Haus, LLC

Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning announced its engagement of Launch Haus, LLC, a venture building firm and digital holding company specializing in direct response marketing. Moving forward, Launch Haus is expected to play an “integral part” in directing CIIX’s corporate organization, as well as its planned launch of direct-to-consumer ecommerce and network marketing business divisions. “Launch Haus is the perfect firm to oversee CIIX's direct response marketing campaign which will include significant direct-to-consumer ecommerce channels such as Amazon and development of the Company's international network marketing platform as we begin to drive revenues in the coming…

MondayJun 05, 2017 12:12 pm

NetworkNewsBreaks – AntriaBio (ANTB) Files IND Application for Diabetes Candidate, Plans for Phase 1 First-in-Human Clinical Trial; Shares Lower

Shares of AntriaBio (OTCQB: ANTB) are 10% lower in morning trade after the biopharmaceutical company said it has filed an Investigational New Drug (IND) application with the FDA for AB101, the company’s once-weekly basal insulin for patients with diabetes mellitus. AntriaBio said it intends to subsequently initiate a phase 1 first-in-human clinical study to assess the safety and tolerability, pharmacokinetics and time-action profile of single ascending doses of AB101, administered to subjects with Type 1 diabetes mellitus. To view the full press release, visit: http://nnw.fm/1oHbk About AntriaBio, Inc. AntriaBio is a patient-centric biopharmaceutical growth company specializing in the development of…

FridayJun 02, 2017 11:34 am

NetworkNewsBreak – Asure Software, Inc. (NASDAQ: ASUR) Engages ROTH Capital as Sole Book-Running Manager in $29.5M Public Offering

Asure Software (NASDAQ: ASUR) has successfully completed an underwritten public offering of 2,185,000 shares of its common stock at the public offering price of $13.50 per share, which includes the sale of 285,000 additional shares pursuant to the full exercise of the over-allotment option granted to the underwriters. ROTH Capital Partners acted as the sole book-running manager for the offering. Gross proceeds for Asure totaled $29.5 million, which the company plans to use toward general corporate purposes and to potentially acquire or invest in complementary businesses, assets or technologies. The company has not entered into any definitive agreement with respect…

FridayJun 02, 2017 11:29 am

NetworkNewsBreak – CytoDyn Inc. (CYDY) Secures Spot at 7th Annual LD Micro Invitational

CytoDyn Inc. (OTCQB: CYDY) announced that its president and CEO, Nader Pourhassan, Ph.D., will be presenting at the 7th Annual LD Micro Invitational on Tuesday next week at noon Pacific time. Investors who wish to have a one-on-one meeting with management should contact LD Micro via the conference website at https://www.ldmicro.com/events. Those unable to attend will be able to watch a live webcast of the presentation on the Company’s website http://www.cytodyn.com under the Investors section/IR Calendar. To view the full press release, visit: http://nnw.fm/SD9iU About CytoDyn CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

Breaks Categories: News